# Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

> **NCT01129557** · PHASE4 · TERMINATED · sponsor: **Columbia University** · enrollment: 46 (actual)

## Conditions studied

- Proteinuric Kidney Disease
- Diabetic Nephropathy
- Hypertensive Nephrosclerosis
- IgA Nephropathy
- Focal Segmental Glomerulosclerosis
- Glomerulopathy (Obesity-associated)
- Glomerulonephritis, Membranous

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Valsartan

## Key facts

- **NCT ID:** NCT01129557
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2012-01
- **Final completion:** 2012-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2014-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01129557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01129557, "Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01129557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*